ESR1 and breast cancer: In addition, previous studies demonstrated that ESR1 positively correlates with the survival rate in breast cancer patients,51 and silencing ESR1 induces EMT and endocrine drug resistance,15, 52 Supporting the results of this study that LINC01116 positively correlates with better survival rate in ER+ breast cancer.